Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Kopetz, S. [1 ]
Abbruzzese, J. L. [1 ]
Eng, C. [1 ]
Adinin, R. B. [1 ]
Morris, J. [1 ]
Wolff, R. A. [1 ]
Lin, E. [1 ]
Chang, D. Z. [1 ]
Hoff, P. [1 ]
Bogaard, K. [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3579
引用
收藏
页码：165S / 165S
页数：1
相关论文
共 50 条
  • [1] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [2] Aviri, a large phase II trial of first-line bevacizumab plus infusional 5-FU/leucovorin and irinotecan (FOLFIRI) in metastatic CRC
    Sobrero, Alberto
    Ackland, Stephen
    Carrion, Ramon Perez
    Chiarra, Silvana
    Clarke, Stephen
    Giron, Carlos Garcia
    Langer, Bernd
    Andre, Niko
    Young, Scott
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [3] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer: Final results
    Kopetz, S.
    Glover, K.
    Eng, C.
    Wolff, R.
    Chang, D.
    Adinin, R.
    Morris, J.
    Abbruzzese, S.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [5] Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer
    Sobrero, Alberto
    Ackland, Stephen
    Clarke, Stephen
    Perez-Carrion, Ramon
    Chiara, Silvia
    Gapski, John
    Mainwaring, Paul
    Langer, Bernd
    Young, Scott
    ONCOLOGY, 2009, 77 (02) : 113 - 119
  • [6] Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI
    Sobrero, A. F.
    Young, S.
    Balcewicz, M.
    Chiarra, S.
    Perez Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Results of a phase II study assessing efficacy and tolerance of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI plus B) in first-line metastatic colorectal cancer (MCRC): The Omega Trial (NTC 00467142)
    Robert, Jacques
    Becouarn, Yves
    Cany, Laurent
    Pulido, Marina
    Dauba, Jerome
    Beyssac, Richard
    Bechade, Dominique
    Lalet, Caroline
    Mathoulin-Pelissier, Simone
    Brunet, Rene
    Fonck, Marianne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] PHASE II STUDY OF FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) WITH GONO-FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) PLUS BEVACIZUMAB (BV)
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Ciprotti, M.
    Donati, S.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 137
  • [9] A Randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer
    Underhill, Craig
    Goldstein, David
    Gorbounova, Vera A.
    Biakhov, Mikhail Y.
    Bazin, Igor S.
    Granov, Dmitry A.
    Hossain, Anwar M.
    Blatter, Johannes
    Kaiser, Christopher
    Ma, Doreen
    ONCOLOGY, 2007, 73 (1-2) : 9 - 20
  • [10] A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer
    Underhill, Craig R.
    Goldstein, David
    Gorbunova, Vera A.
    Biakhov, Mikhail Y.
    Bazin, Igor S.
    Melemed, Allen
    Hossain, Anwar
    Granov, Dmitry A.
    ANNALS OF ONCOLOGY, 2006, 17 : 118 - 118
12345